Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-26T11:18:52.284Z Has data issue: false hasContentIssue false
  • English
  • Français

Psychofarmacological approach for Binge- eating disorders

Published online by Cambridge University Press:  01 September 2022

V. Muñoz Martinez ,
L. Beato-Fernández  and
E. Segura-Escobar
V. Muñoz Martinez*
Affiliation:
Hospital General Universitario de Ciudad Real, Adolescents Inpatient Unit., Ciudad Real, Spain Hospital General Universitario de Ciudad Real, Adolescente Inpatient Unit., Ciudad Real, Spain
L. Beato-Fernández
Affiliation:
Hospital General Universitario de Ciudad Real, Chief Of Psychiatry, Ciudad Real, Spain
E. Segura-Escobar
Affiliation:
Hospital General Universitario de Ciudad Real, Adolescents Inpatient Unit., Ciudad Real, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Binge-eating disorder (BED), is one of the most common eating disorder. Treatment aims to reduce binge-eating frequency and disordered eating–related cognitions, improve metabolic health and weight, and regulate mood (in patients with coexisting depression or anxiety)

Objectives

The aim of this study was to examine the efficacy of lisdexamfetamine dimesylate in a simple of 50 women with a binge eating disorder diagnosis compare with selective serotonin reuptake inhibitor

Methods

Two groups were made, one with lisdexamfetamine and the other with selective serotonin reuptake inhibitor (fluoxetine). 20 women were in each group (total n=40). The doses depend of the binge symptoms and rates were from 30 to 70md/day for lisdexamfetamine and for fluoxetine the doses were from 20 to 60mg/day.

Results

Binge behaviors decreased with a 50mg/day dose of lisdexamfetamine. The 70mg/day doses present also less binge behaviors but also more adverse events. The 30mg/day doses did not decrease binge-eating behaviors.

Conclusions

Lisdexamfetamine is the first pharmacological agent to receive FDA approval for use in adults with moderate to severe binge eating disorder. This study supports further assessment of lisdexamfetamine as a treatment option for decreasing binge eating behavior and also symptoms associated such as anxiety and obsessive and compulsive features in adults.Increased efficacy with increasing dosages of lisdexamfetamine suggests a dose-response relationship until 50mg/day. Women with a dose of 50mg/day of lisdexamfetamine report less adverse event, more adherence to treatment and improve their eating behaviors.

Disclosure

No significant relationships.

Keywords

binge eating disorderLisdexanfetamineFluoxetineeating disorder
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S230
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.